Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type

Pierre N. Tariot, Bonnie Goldstein, Carol Ann Podgorski, Christopher Cox, Nancy Frambes

Research output: Contribution to journalArticle

Abstract

As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-tPlanmoderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug- placebo difference in any outcome measure. Selegiline did not show short- term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.

Original languageEnglish (US)
Pages (from-to)145-154
Number of pages10
JournalAmerican Journal of Geriatric Psychiatry
Volume6
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Selegiline
Alzheimer Disease
Dementia
Outpatients
Placebos
Cross-Over Studies
Cognition
Inpatients
Outcome Assessment (Health Care)
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. / Tariot, Pierre N.; Goldstein, Bonnie; Podgorski, Carol Ann; Cox, Christopher; Frambes, Nancy.

In: American Journal of Geriatric Psychiatry, Vol. 6, No. 2, 1998, p. 145-154.

Research output: Contribution to journalArticle

Tariot, Pierre N. ; Goldstein, Bonnie ; Podgorski, Carol Ann ; Cox, Christopher ; Frambes, Nancy. / Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. In: American Journal of Geriatric Psychiatry. 1998 ; Vol. 6, No. 2. pp. 145-154.
@article{06d9ec8f4b3d40ad9ae8fb6c3a949604,
title = "Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type",
abstract = "As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-tPlanmoderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug- placebo difference in any outcome measure. Selegiline did not show short- term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.",
author = "Tariot, {Pierre N.} and Bonnie Goldstein and Podgorski, {Carol Ann} and Christopher Cox and Nancy Frambes",
year = "1998",
doi = "10.1097/00019442-199805000-00008",
language = "English (US)",
volume = "6",
pages = "145--154",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type

AU - Tariot, Pierre N.

AU - Goldstein, Bonnie

AU - Podgorski, Carol Ann

AU - Cox, Christopher

AU - Frambes, Nancy

PY - 1998

Y1 - 1998

N2 - As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-tPlanmoderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug- placebo difference in any outcome measure. Selegiline did not show short- term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.

AB - As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-tPlanmoderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug- placebo difference in any outcome measure. Selegiline did not show short- term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0031946037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031946037&partnerID=8YFLogxK

U2 - 10.1097/00019442-199805000-00008

DO - 10.1097/00019442-199805000-00008

M3 - Article

C2 - 9581210

AN - SCOPUS:0031946037

VL - 6

SP - 145

EP - 154

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 2

ER -